CU23734A1 - Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas - Google Patents

Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas

Info

Publication number
CU23734A1
CU23734A1 CU20090203A CU20090203A CU23734A1 CU 23734 A1 CU23734 A1 CU 23734A1 CU 20090203 A CU20090203 A CU 20090203A CU 20090203 A CU20090203 A CU 20090203A CU 23734 A1 CU23734 A1 CU 23734A1
Authority
CU
Cuba
Prior art keywords
present
relates
infectious diseases
polypeptides
chronic infectious
Prior art date
Application number
CU20090203A
Other languages
English (en)
Inventor
Perera Gabriel Marquez
Rodriguez Saumel Perez
Martinez Karina Garcia
Monzon Kalet Leon
Roche Diamile Gonzalez
Portilla Tania Carmenate
Davila Agustin Bienvenido Lage
Original Assignee
Centro Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43646474&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU23734(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centro Inmunologia Molecular filed Critical Centro Inmunologia Molecular
Priority to CU20090203A priority Critical patent/CU23734A1/es
Priority to ARP100104366A priority patent/AR079197A1/es
Priority to BR112012012025A priority patent/BR112012012025B8/pt
Priority to US13/512,429 priority patent/US8759486B2/en
Priority to CA2781173A priority patent/CA2781173C/en
Priority to SG2012039053A priority patent/SG181089A1/en
Priority to EA201290395A priority patent/EA021867B1/ru
Priority to PH1/2012/500812A priority patent/PH12012500812A1/en
Priority to MX2012006077A priority patent/MX2012006077A/es
Priority to NZ599792A priority patent/NZ599792A/en
Priority to KR1020127010828A priority patent/KR101484590B1/ko
Priority to JP2012540281A priority patent/JP5680661B2/ja
Priority to MYPI2012002130A priority patent/MY162324A/en
Priority to HK12110868.4A priority patent/HK1169961B/xx
Priority to CN201080053369.9A priority patent/CN102665754B/zh
Priority to PCT/CU2010/000005 priority patent/WO2011063770A2/es
Priority to ES10803437.2T priority patent/ES2643465T3/es
Priority to PE2012000720A priority patent/PE20121636A1/es
Priority to EP10803437.2A priority patent/EP2505206B1/en
Priority to AU2010324254A priority patent/AU2010324254B2/en
Publication of CU23734A1 publication Critical patent/CU23734A1/es
Priority to ECSP12011803 priority patent/ECSP12011803A/es
Priority to TNP2012000182A priority patent/TN2012000182A1/en
Priority to CL2012001030A priority patent/CL2012001030A1/es
Priority to ZA2012/03762A priority patent/ZA201203762B/en
Priority to CO12095471A priority patent/CO6501124A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se relaciona en general con ploipéptidos cuya secuencia primaria tiene una alta homología con la secuencia de la interleucina 2 humana (IL-2) con algunas mutaciones puntuales en la secuencia de la IL-2 nativa. Los polipéptidos de la presente invención tienen un efecto inmunomodulador sobre el sistema inmune, que es selectivo/preferencial sobre células T reguladoras. La presente invención también se relaciona con polipéptidos específicos cuya secuencia de aminoácidos es divulgada en la presente invención. En otro aspecto la presente invención se relaciona con las composiciones farmacéuticas que comprenden como principio activo los polipéptidos divulgados. Por último, la presente invención se relaciona con el uso terapéutico de los polipéptidos y composiciones farmacéuticas divulgados dado su efecto modulador del sistema inmune sobre patologías como cáncer y enfermedades infecciosas crónicas.
CU20090203A 2009-11-27 2009-11-27 Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas CU23734A1 (es)

Priority Applications (25)

Application Number Priority Date Filing Date Title
CU20090203A CU23734A1 (es) 2009-11-27 2009-11-27 Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas
ARP100104366A AR079197A1 (es) 2009-11-27 2010-11-25 Polipeptidos inmunomoduladores derivados de la il-2 y su uso terapeutico en cancer y en infecciones cronicas
AU2010324254A AU2010324254B2 (en) 2009-11-27 2010-11-26 Immunomodulatory polypeptides derived from IL- 2 and their use thereof in the therapeutic of cancer and chronic infections
MYPI2012002130A MY162324A (en) 2009-11-27 2010-11-26 Immunomodulatory polypeptides derived from il-2 and their use thereof in the therapeutic of cancer and chronic infections
HK12110868.4A HK1169961B (en) 2009-11-27 2010-11-26 Immunomodulatory polypeptides derived from il-2 and their use thereof in the therapeutic of cancer and chronic infections
CA2781173A CA2781173C (en) 2009-11-27 2010-11-26 Immunomodulatory polypeptides derived from il-2 and their use thereof in the therapeutic of cancer and chronic infections
SG2012039053A SG181089A1 (en) 2009-11-27 2010-11-26 Immunomodulatory polypeptides derived from il- 2 and their use thereof in the therapeutic of cancer and chronic infections
EA201290395A EA021867B1 (ru) 2009-11-27 2010-11-26 Иммуномодулирующие полипептиды, полученные из il-2, и их применение для лечения рака и хронических инфекций
PH1/2012/500812A PH12012500812A1 (en) 2009-11-27 2010-11-26 Immunomodulatory polypeptides derived from il-2 and their use thereof in the therapeutic of cancer and chronic infections
MX2012006077A MX2012006077A (es) 2009-11-27 2010-11-26 Polipeptidos inmunomoduladores derivados de la interleucina 2 y su uso terapeutico en cancer y en infecciones cronicas.
NZ599792A NZ599792A (en) 2009-11-27 2010-11-26 Immunomodulatory polypeptides derived from il- 2 and their use thereof in the therapeutic of cancer and chronic infections
KR1020127010828A KR101484590B1 (ko) 2009-11-27 2010-11-26 인터류킨-2에서 유래된 면역조절성 폴리펩티드 및 이를 이용한 암 및 만성감염의 치료에서의 그것의 용도
JP2012540281A JP5680661B2 (ja) 2009-11-27 2010-11-26 Ｉｌ−２に由来する免疫調節ポリペプチド並びに癌及び慢性感染症の治療におけるその使用
BR112012012025A BR112012012025B8 (pt) 2009-11-27 2010-11-26 polipeptídeo imunomodulador derivado da interleucina-2, proteína de fusão, composição farmacêutica e usos do polipeptídeo e da proteína de fusão
US13/512,429 US8759486B2 (en) 2009-11-27 2010-11-26 Immunomodulatory interleukin-2 polypeptides and methods of treating melanoma
CN201080053369.9A CN102665754B (zh) 2009-11-27 2010-11-26 衍生自il-2的免疫调节多肽及其在治疗癌症和慢性感染中的用途
PCT/CU2010/000005 WO2011063770A2 (es) 2009-11-27 2010-11-26 Polipéptidos inmunomoduladores derivados de la il-2 y su uso terapéutico en cáncer y en infecciones crónicas
ES10803437.2T ES2643465T3 (es) 2009-11-27 2010-11-26 Polipéptidos inmunomoduladores derivados de IL-2 y su uso terapéutico contra el cáncer e infecciones crónicas
PE2012000720A PE20121636A1 (es) 2009-11-27 2010-11-26 Polipeptidos inmunomoduladores derivados de la il-2 y su uso terapeutico en cancer y en infecciones cronicas
EP10803437.2A EP2505206B1 (en) 2009-11-27 2010-11-26 Immunomodulatory polypeptides derived from il-2 and their use thereof in the therapeutic of cancer and chronic infections
ECSP12011803 ECSP12011803A (es) 2009-11-27 2012-04-17 Polipéptidos inmunomoduladores derivados de la il-2 y su uso terapéutico en cáncer y en infecciones crónicas
TNP2012000182A TN2012000182A1 (en) 2009-11-27 2012-04-20 Immunomodulatory polypeptides derived from il-2 and their use thereof in the therapeutic of cancer and chronic infections
CL2012001030A CL2012001030A1 (es) 2009-11-27 2012-04-23 Polipeptido inmunomodulador derivado de la il-2 que comprende varias mutaciones respecto a la secuencia de il-2 nativa que inhibe preferencialmente la actividad de il- 2 sobre celulas t reguladoras in vitro; proteína de fusión que lo comprende; y su uso para tratar cancer.
ZA2012/03762A ZA201203762B (en) 2009-11-27 2012-05-23 Immunomodulatory polypeptide derived from il-2 and their use thereof in the therapeutic of cancer and chronic infections
CO12095471A CO6501124A2 (es) 2009-11-27 2012-06-06 Polipeptidos inmunomoduladores derivados se la il 2 y su uso terapeutico en cancer y en infecciones crónicas

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20090203A CU23734A1 (es) 2009-11-27 2009-11-27 Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas

Publications (1)

Publication Number Publication Date
CU23734A1 true CU23734A1 (es) 2011-11-15

Family

ID=43646474

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20090203A CU23734A1 (es) 2009-11-27 2009-11-27 Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas

Country Status (24)

Country Link
US (1) US8759486B2 (es)
EP (1) EP2505206B1 (es)
JP (1) JP5680661B2 (es)
KR (1) KR101484590B1 (es)
CN (1) CN102665754B (es)
AR (1) AR079197A1 (es)
AU (1) AU2010324254B2 (es)
BR (1) BR112012012025B8 (es)
CA (1) CA2781173C (es)
CL (1) CL2012001030A1 (es)
CO (1) CO6501124A2 (es)
CU (1) CU23734A1 (es)
EA (1) EA021867B1 (es)
EC (1) ECSP12011803A (es)
ES (1) ES2643465T3 (es)
MX (1) MX2012006077A (es)
MY (1) MY162324A (es)
NZ (1) NZ599792A (es)
PE (1) PE20121636A1 (es)
PH (1) PH12012500812A1 (es)
SG (1) SG181089A1 (es)
TN (1) TN2012000182A1 (es)
WO (1) WO2011063770A2 (es)
ZA (1) ZA201203762B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6093712B2 (ja) 2010-12-22 2017-03-08 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー インターロイキン２のスーパーアゴニストおよびアンタゴニスト
WO2015042707A1 (en) 2013-09-24 2015-04-02 Medicenna Therapeutics Pte Ltd Interleukin-2 fusion proteins and uses thereof
EP3320916B1 (en) 2014-03-17 2021-09-15 BUNDESREPUBLIK DEUTSCHLAND letztvertreten durch das Robert Koch-Institut vertreten durch seinen Präsidenten A medicament for use in a method of inducing or extending a cellular cytotoxic immune response
WO2015164815A1 (en) * 2014-04-24 2015-10-29 The Board Of Trustees Of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
WO2017096262A1 (en) 2015-12-04 2017-06-08 Jomoco, Corp. Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates
AU2017335771A1 (en) 2016-09-28 2019-02-28 Musc Foundation For Research Development Antibodies that bind interleukin-2 and uses thereof
CU24483B1 (es) 2016-11-15 2020-04-02 Ct Inmunologia Molecular Método para incrementar los niveles de secreción de la interleucina-2
AU2018226857B2 (en) 2017-03-03 2025-01-02 Obsidian Therapeutics, Inc. Compositions and methods for immunotherapy
EP3596108A4 (en) 2017-03-15 2020-12-23 Pandion Operations, Inc. TARGETED IMMUNOTOLERANCE
AU2018273914A1 (en) 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
JP7433051B2 (ja) 2017-06-19 2024-02-19 メディシナ セラピューティクス インコーポレイテッド Ｉｌ－２スーパーアゴニスト、アゴニスト、およびそれらの融合体の使用および方法
MA49767A (fr) 2017-08-03 2021-05-26 Synthorx Inc Conjugués de cytokine pour le traitement de maladies auto-immunes
US20200299349A1 (en) 2017-11-21 2020-09-24 The Board Of Trustees Of The Leland Stanford Junior University Partial agonists of interleukin-2
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
BR112020018709A2 (pt) 2018-03-28 2021-01-05 Bristol-Myers Squibb Company Proteínas de fusão do receptor alfa de interleucina-2/interleucina-2 e métodos de uso
BR112020019639A2 (pt) * 2018-03-28 2021-01-05 Ascendis Pharma Oncology Division A/S Conjugados de il-2
US20210253671A1 (en) * 2018-06-07 2021-08-19 Prottech Inc. Pharmaceutical Composition Containing Fusion Protein and Use Thereof
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
CA3127689A1 (en) 2019-02-06 2020-08-13 Synthorx, Inc. Il-2 conjugates and methods of use thereof
TW202110885A (zh) 2019-05-20 2021-03-16 美商潘迪恩治療公司 靶向ＭＡｄＣＡＭ之免疫耐受性
AU2020347154A1 (en) 2019-09-10 2022-03-03 Synthorx, Inc. IL-2 conjugates and methods of use to treat autoimmune diseases
MX2022007605A (es) 2019-12-23 2022-07-19 Synthorx Inc Metodos de preparacion de n6-((2-azidoetoxi)carbonil)lisina.
CA3166509A1 (en) 2020-01-14 2021-07-22 Synthekine, Inc. Biased il2 muteins methods and compositions
WO2021168079A1 (en) 2020-02-21 2021-08-26 Pandion Operations, Inc. Tissue targeted immunotolerance with a cd39 effector
IL298642A (en) 2020-06-03 2023-01-01 Ascendis Pharma Oncology Div A/S il-2 sequences and uses thereof
EP4208474A2 (en) * 2020-09-01 2023-07-12 Takeda Pharmaceutical Company Limited Interleukin-2 muteins and uses thereof
PE20240123A1 (es) 2020-09-04 2024-01-22 Shandong Simcere Biopharmaceutical Co Ltd Mutante de il-2 y aplicacion de este
EP4232071A4 (en) 2020-10-23 2024-08-28 Asher Biotherapeutics, Inc. FUSIONS WITH CD8 ANTIGEN-BINDING MOLECULES TO MODULATE IMMUNE CELL FUNCTION
IL302114A (en) 2020-10-29 2023-06-01 Bristol Myers Squibb Co Fusion proteins for the treatment of disease
CN117321189A (zh) 2021-04-30 2023-12-29 泰根制药有限公司 淋巴细胞的单血管扩增
EP4463135A2 (en) 2022-01-10 2024-11-20 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
JP2025541604A (ja) 2022-11-02 2025-12-22 ティゲン・ファーマ・ソシエテ・アノニム リンパ球の拡大
WO2024261339A1 (en) 2023-06-23 2024-12-26 Tigen Pharma Sa Lymphocyte-stimulatory matrix (lsm) and uses thereof for expansion of lymphocyte populations

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4853332A (en) 1982-10-19 1989-08-01 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US5116943A (en) 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
JP3024311B2 (ja) 1991-10-03 2000-03-21 味の素株式会社 Ｉｌ−２受容体重鎖に結合するポリペプチド
US5229109A (en) 1992-04-14 1993-07-20 Board Of Regents, The University Of Texas System Low toxicity interleukin-2 analogues for use in immunotherapy
US5635597A (en) 1994-05-27 1997-06-03 Affymax Technologies, N.V. Peptides that bind IL-2 receptors
US6955807B1 (en) 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
US6168785B1 (en) 1998-07-16 2001-01-02 Institut Pasteur Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents
US6906170B1 (en) 1998-08-21 2005-06-14 Yeda Research And Development Co. Ltd. Anti-inflammatory peptides derived from IL-2 and analogues thereof
BR0214650A (pt) 2001-12-04 2005-05-03 Merck Patent Gmbh Imunocitoquinas com seletividade modulada
WO2005007121A2 (en) 2003-07-18 2005-01-27 Massachusetts Institute Of Technology Mutant interleukin-2(il-2) polypeptides
CA2656700A1 (en) * 2006-07-06 2008-01-10 Merck Patent Gesellschaft Mit Beschraenkter Haftung Compositions and methods for enhancing the efficacy of il-2 mediated immune responses
WO2009061853A2 (en) 2007-11-05 2009-05-14 Massachusetts Institute Of Technology Mutant interleukin-2 (il-2) polypeptides
DE102008023820A1 (de) * 2008-05-08 2009-11-12 Aicuris Gmbh & Co. Kg Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen

Also Published As

Publication number Publication date
CA2781173A1 (en) 2011-06-03
HK1169961A1 (en) 2013-02-15
AU2010324254B2 (en) 2014-01-09
NZ599792A (en) 2014-01-31
JP5680661B2 (ja) 2015-03-04
SG181089A1 (en) 2012-07-30
MY162324A (en) 2017-05-31
US8759486B2 (en) 2014-06-24
BR112012012025A2 (pt) 2016-05-17
AU2010324254A1 (en) 2012-05-31
AR079197A1 (es) 2012-01-04
US20120315245A1 (en) 2012-12-13
EA021867B1 (ru) 2015-09-30
CO6501124A2 (es) 2012-08-15
PH12012500812A1 (en) 2016-01-27
EA201290395A1 (ru) 2012-10-30
CA2781173C (en) 2015-10-13
CL2012001030A1 (es) 2012-07-20
CN102665754B (zh) 2014-03-12
JP2013512200A (ja) 2013-04-11
ECSP12011803A (es) 2012-07-31
WO2011063770A3 (es) 2011-09-09
PE20121636A1 (es) 2012-12-03
MX2012006077A (es) 2012-09-07
WO2011063770A2 (es) 2011-06-03
ES2643465T3 (es) 2017-11-23
TN2012000182A1 (en) 2013-12-12
KR101484590B1 (ko) 2015-01-22
CN102665754A (zh) 2012-09-12
BR112012012025B1 (pt) 2021-05-11
BR112012012025B8 (pt) 2021-05-25
EP2505206B1 (en) 2017-09-27
ZA201203762B (en) 2013-01-30
EP2505206A2 (en) 2012-10-03
KR20120106728A (ko) 2012-09-26

Similar Documents

Publication Publication Date Title
CU23734A1 (es) Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas
CU23923B1 (es) Polipéptidos derivados de la il-2 con actividad agonista
BR112017025108A2 (pt) compostos seletivos de pyy e usos dos mesmos
CY1119616T1 (el) Συζευγματα ανθρωπινου αντισωματος-φαρμακου κατα του ιστικου παραγοντα
CR20160117A (es) Anticuerpos contra el inhibidor del activador de plasminógeno tipo 1 (pai-1) y usos de los mismos
BR112015011158A2 (pt) triazolopirazina
BR112012020839A2 (pt) vacinas para uso na profilaxe e tratamento de doença de vírus da influenza
NI201500013A (es) Tratamiento de enfermedades inmuno - relacionadas e inflamatorias.
CO7010783A2 (es) Proteína naglu humana recombinante y usos de la misma
ECSP20000655A (es) AGENTES DE iARN PARA LA INHIBICIÓN DE LA EXPRESIÓN DE ALFA-ENaC Y MÉTODOS DE USO
CL2012001836A1 (es) Compuestos de pirazol, antagonista de crth2; composicion farmacéutica; uso en el tratamiento de trastornos inflamatorios, infecciosos, inmunoreguladores, enfermedades respiratorias, gastrointestinales o dolencias, entre otros.
MX2020005235A (es) Celula humana transformada y uso de la misma.
CR20140475A (es) Agentes terapéuticos para administración subcutánea optimizados
BR112015023793A2 (pt) composições e métodos de terapias para indução de tolerância imune a substituição do fator vii em indivíduos com hemofilia a
EP4321218A3 (en) Cancer stem cell targeted cancer vaccines
CY1119073T1 (el) Ισομορφες γλυκοζυλιωσης ανθρωπινης ιστικης καλλικρεινης 1
BR112015015250A2 (pt) derivados de pirrolidina, composições farmacêuticas e usos dos mesmos
BR112014028443A8 (pt) Composição estéril esterilizada com radiação
MX392532B (es) Glicoproteinas recombinantes y sus usos.
AR093391A1 (es) POLIPEPTIDOS DERIVADOS DEL TGFb Y SUS USOS
PY1939780A (es) Composiciones farmacéuticas para el tratamiento de la deficiencia de esfingomielinasa ácida
AR112754A1 (es) AGENTES DE iARN PARA LA INHIBICIÓN DE LA EXPRESIÓN DE a-ENaC Y MÉTODOS DE USO
BR112018016715A2 (pt) ?formulações de oritavancina?
TR201201022A2 (tr) Akciğer hastalıkları, karaciğer hastalıkları ve çeşitli enfeksiyonların semptomatik ve/veya terapötik tedavisinde kullanılan farmasötik bileşimler.
EA201992775A3 (ru) Конъюгаты антител человека против тканевого фактора с лекарственными препаратами

Legal Events

Date Code Title Description
FG Grant of patent